Genedrive PLC

03 March 2021

genedrive plc

("genedrive" or the "Company")

Antibiotic Induced Hearing Loss update

New clinical guidance in the UK supports assay

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on its Antibiotic Induced Hearing Loss ("AIHL") assay.

As announced on the 3 December 2020, an 11 month implementation trial at Manchester University NHS Foundation Trust and and Liverpool Women's Hospital successfully concluded in November 2020. The results of the study will be published in a peer reviewed journal. The study's primary outcomes were very positive, showing genedrive's utility as the world's first rapid genetic test in an emergency care neonatal setting. In excess of 750 babies were tested and 160 hospital staff were trained to provide rapid testing in this critical care setting.

Since completion of the trial, there has been new clinical guidance in the UK(1) on the importance of the management of specific genetic mutations and their role in hearing loss as a result of antibiotics ("ototoxicity"). Government and Society guidance are considered a key factor influencing the speed and extent of future adoption. The Company and Inspiration Healthcare Group plc (AIM: IHC), the distribution partner for the AIHL assay, believe this will lead to increased demand for the genedrive AIHL test in the UK. This new government guidance reminds healthcare professionals about the impact of antibiotic related ototoxicity and to consider the need for genetic testing prior to initiation of treatment. genedrive's assay is the only commercial point of care test available for the testing of MT-RNR1, the most important mutation contributing to AIHL in infants.

The launch of the genedrive AIHL assay remains on track for summer 2021 and the Company is enthusiastic about both the commercial prospects and the clinical benefits of this novel test to prevent potential irreversible hearing loss and this test becoming a standard of care. The Company is executing initial stage key opinion leader engagement in the UK alongside Inspriration Healthcare in preparation for commercial launch.

David Budd, CEO of genedrive plc, said: "We had the privilege of working with Manchester University NHS Foundation Trust and Liverpool Women's Hospital throughout 2020 on the first deployment globally of a point of care test system to screen for MT-RNR1 - a mitochondrial mutation closely associated with ototoxicity in infants. Despite the emergence of COVID-19, our clinical partners showed huge dedication in keeping this important project on-track, becoming the first in the world to generate valuable information on the utility of this approach in an emergency care setting. As we see updated guidance and greater awareness to the requirement for genetic testing, we only expect increased interest in our novel assay."

(1) https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations

For further details please contact:

 genedrive plc                                                                 +44 (0)161 989 0245 
 David Budd: CEO / Matthew Fowler: 
 Peel Hunt LLP (Nominated Adviser 
  and Joint Broker)                                                            +44 (0)20 7418 8900 
 James Steel / Oliver Jackson 
            finnCap (Joint Broker)                                             +44 (0)20 7220 0500 
            Geoff Nash / Kate Bannatyne / Alice 
 Walbrook PR Ltd (Media & Investor                 +44 (0)20 7933 8780 or genedrive@walbrookpr.com 
                                                                 +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                                741 001 

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive(R) Point of Care version of the assay, both based on Genedrive(R) chemistry.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 03, 2021 02:00 ET (07:00 GMT)